Liquidia's (LQDA) Buy Rating Reiterated at Needham & Company LLC

Liquidia (NASDAQ:LQDA - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently have a $25.00 target price on the stock. Needham & Company LLC's target price indicates a potential upside of 55.64% from the company's previous close.

LQDA has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $29.00 price target on shares of Liquidia in a report on Monday. Raymond James raised their price target on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday. Finally, Scotiabank restated an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Liquidia has a consensus rating of "Buy" and a consensus target price of $27.13.

Liquidia Price Performance

Liquidia stock traded up $0.80 during midday trading on Monday, reaching $16.06. The company had a trading volume of 352,473 shares, compared to its average volume of 1,002,245. The company has a market capitalization of $1.37 billion, a P/E ratio of -9.77 and a beta of 0.24. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.81. The firm's fifty day simple moving average is $14.25 and its 200-day simple moving average is $13.18.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, analysts expect that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger Jeffs sold 14,130 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. The trade was a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,138 shares of company stock valued at $450,233. Company insiders own 26.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in shares of Liquidia by 265.0% in the third quarter. Barclays PLC now owns 99,984 shares of the company's stock worth $999,000 after buying an additional 72,591 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after purchasing an additional 210,753 shares during the last quarter. DMC Group LLC grew its holdings in Liquidia by 17.4% during the 4th quarter. DMC Group LLC now owns 16,302 shares of the company's stock worth $192,000 after acquiring an additional 2,419 shares during the last quarter. Catalina Capital Group LLC lifted its position in Liquidia by 6.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock valued at $215,000 after purchasing an additional 1,125 shares during the period. Finally, Rhumbline Advisers lifted its position in Liquidia by 3.5% during the 4th quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock valued at $948,000 after purchasing an additional 2,741 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.